Immuron (IMRN) Interest Expenses (2016 - 2025)
Immuron (IMRN) posted quarterly Interest Expenses of -$2.6 billion for Q4 2024, down 65624179.23% year-over-year from N/an in Q1 2024, and down 65624179.23% quarter-over-quarter from $4007.0 in Q4 2023.
Immuron (IMRN) Interest Expenses (2016 - 2025) Analysis & Trends
Immuron's Interest Expenses history runs 9 years deep, the most recent figure standing at -$2.6 billion for Q4 2024.
- In Q4 2024, Interest Expenses fell 65624179.23% year-over-year to -$2.6 billion; the TTM figure through Sep 2025 stood at -$2.6 billion (down 65624179.23% YoY), while the FY2025 annual figure was -$7305.0, up 3.58% from the prior year.
- Interest Expenses for Q4 2024 stood at -$2.6 billion, down from $4007.0 in the prior quarter.
- The five-year high for Interest Expenses was $4007.0 in Q4 2023, with the low at -$2.6 billion in Q4 2024.
- The 5-year median for Interest Expenses is -$2281.2 (2021), against an average of -$438.3 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses soared 189.02% in 2023, then slumped 65624179.23% in 2024.
- Immuron's Interest Expenses stood at -$27500.0 in 2020, then jumped by 99.78% to -$61.49 in 2021, then sank by 7219.95% to -$4501.0 in 2022, then jumped by 189.02% to $4007.0 in 2023, then plunged by 65624179.23% to -$2.6 billion in 2024.
- Business Quant data shows IMRN's Interest Expenses at -$2.6 billion in Q4 2024, $4007.0 in Q4 2023, and $1126.9 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | -7,305.00 |
| Sep 2, 2025 | -7,305.00 |
| Dec 31, 2024 | -2.63 Bn |
| Dec 31, 2024 | -2.63 Bn |
| Dec 31, 2023 | 4,007.00 |
| Dec 31, 2023 | 4,007.00 |
| Jun 30, 2023 | 1,126.86 |
| Jun 30, 2023 | 1,126.86 |
| Dec 31, 2022 | -4,501.00 |
| Dec 31, 2022 | -4,501.00 |
| Dec 31, 2021 | -61.49 |
| Dec 31, 2021 | -61.49 |
| Dec 31, 2020 | -27,500.00 |
| Dec 31, 2020 | -27,500.00 |
| Dec 31, 2019 | -20,501.00 |
| Dec 31, 2019 | -20,501.00 |
| Dec 31, 2018 | -39.00 |
| Dec 31, 2018 | -39.00 |
| Dec 31, 2017 | -2,935.78 |
| Dec 31, 2017 | -2,935.78 |